Search

Your search keyword '"Mikami, Kazuya"' showing total 301 results
Start Over Author "Mikami, Kazuya"
301 results on '"Mikami, Kazuya"'

1. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF‐I, IGF‐II, IGFBP‐1, IGFBP‐2 and IGFBP‐3 in a pooled analysis of 16,024 men from 22 studies

Author

Watts, Eleanor L, Perez‐Cornago, Aurora, Appleby, Paul N, Albanes, Demetrius, Ardanaz, Eva, Black, Amanda, Bueno‐de‐Mesquita, H Bas, Chan, June M, Chen, Chu, Chubb, SA Paul, Cook, Michael B, Deschasaux, Mélanie, Donovan, Jenny L, English, Dallas R, Flicker, Leon, Freedman, Neal D, Galan, Pilar, Giles, Graham G, Giovannucci, Edward L, Gunter, Marc J, Habel, Laurel A, Häggström, Christel, Haiman, Christopher, Hamdy, Freddie C, Hercberg, Serge, Holly, Jeff M, Huang, Jiaqi, Huang, Wen‐Yi, Johansson, Mattias, Kaaks, Rudolf, Kubo, Tatsuhiko, Lane, J Athene, Layne, Tracy M, Le Marchand, Loic, Martin, Richard M, Metter, E Jeffrey, Mikami, Kazuya, Milne, Roger L, Morris, Howard A, Mucci, Lorelei A, Neal, David E, Neuhouser, Marian L, Oliver, Steven E, Overvad, Kim, Ozasa, Kotaro, Pala, Valeria, Pernar, Claire H, Pollak, Michael, Rowlands, Mari‐Anne, Schaefer, Catherine A, Schenk, Jeannette M, Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Touvier, Mathilde, Trichopoulou, Antonia, Tsilidis, Konstantinos K, Van Den Eeden, Stephen K, Weinstein, Stephanie J, Wilkens, Lynne, Yeap, Bu B, Key, Timothy J, Allen, Naomi E, and Travis, Ruth C

Subjects
Cancer, Aging, Urologic Diseases, Adult, Aged, Aged, 80 and over, Anthropometry, Biomarkers, Tumor, Cross-Sectional Studies, Humans, Insulin-Like Growth Factor Binding Proteins, Insulin-Like Growth Factor I, Insulin-Like Growth Factor II, Male, Middle Aged, Neoplasms, Prospective Studies, Young Adult, IGFs, IGFBPs, pooled analysis, correlates, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Insulin-like growth factors (IGFs) and insulin-like growth factor binding proteins (IGFBPs) have been implicated in the aetiology of several cancers. To better understand whether anthropometric, behavioural and sociodemographic factors may play a role in cancer risk via IGF signalling, we examined the cross-sectional associations of these exposures with circulating concentrations of IGFs (IGF-I and IGF-II) and IGFBPs (IGFBP-1, IGFBP-2 and IGFBP-3). The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset includes individual participant data from 16,024 male controls (i.e. without prostate cancer) aged 22-89 years from 22 prospective studies. Geometric means of protein concentrations were estimated using analysis of variance, adjusted for relevant covariates. Older age was associated with higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations of IGF-I, IGF-II and IGFBP-3. Higher body mass index was associated with lower concentrations of IGFBP-1 and IGFBP-2. Taller height was associated with higher concentrations of IGF-I and IGFBP-3 and lower concentrations of IGFBP-1. Smokers had higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations of IGFBP-3 than nonsmokers. Higher alcohol consumption was associated with higher concentrations of IGF-II and lower concentrations of IGF-I and IGFBP-2. African Americans had lower concentrations of IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 and Hispanics had lower IGF-I, IGF-II and IGFBP-3 than non-Hispanic whites. These findings indicate that a range of anthropometric, behavioural and sociodemographic factors are associated with circulating concentrations of IGFs and IGFBPs in men, which will lead to a greater understanding of the mechanisms through which these factors influence cancer risk.

Published
2019

2. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies

Author

Watts, Eleanor L, Appleby, Paul N, Perez-Cornago, Aurora, Bueno-de-Mesquita, H Bas, Chan, June M, Chen, Chu, Cohn, Barbara A, Cook, Michael B, Flicker, Leon, Freedman, Neal D, Giles, Graham G, Giovannucci, Edward, Gislefoss, Randi E, Hankey, Graeme J, Kaaks, Rudolf, Knekt, Paul, Kolonel, Laurence N, Kubo, Tatsuhiko, Le Marchand, Loïc, Luben, Robert N, Luostarinen, Tapio, Männistö, Satu, Metter, E Jeffrey, Mikami, Kazuya, Milne, Roger L, Ozasa, Kotaro, Platz, Elizabeth A, Quirós, J Ramón, Rissanen, Harri, Sawada, Norie, Stampfer, Meir, Stanczyk, Frank Z, Stattin, Pär, Tamakoshi, Akiko, Tangen, Catherine M, Thompson, Ian M, Tsilidis, Konstantinos K, Tsugane, Shoichiro, Ursin, Giske, Vatten, Lars, Weiss, Noel S, Yeap, Bu B, Allen, Naomi E, Key, Timothy J, and Travis, Ruth C

Subjects
Cancer, Clinical Research, Prevention, Urologic Diseases, Prostate Cancer, Aging, Aetiology, 2.1 Biological and endogenous factors, Adult, Aged, Biomarkers, Case-Control Studies, Down-Regulation, Humans, Male, Middle Aged, Neoplasm Grading, Prospective Studies, Prostatic Neoplasms, Protective Factors, Risk Assessment, Risk Factors, Testosterone, Time Factors, Androgens Pooled analysis, Prospective studies, Prostate cancer, Sex hormones, Epidemiology, Androgens, Pooled analysis, Clinical Sciences, Urology & Nephrology
Abstract

BackgroundExperimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting.ObjectiveTo examine whether men with low concentrations of circulating free testosterone have a reduced risk of prostate cancer.Design, setting, and participantsAnalysis of individual participant data from 20 prospective studies including 6933 prostate cancer cases, diagnosed on average 6.8 yr after blood collection, and 12 088 controls in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group.Outcome measurements and statistical analysisOdds ratios (ORs) of incident overall prostate cancer and subtypes by stage and grade, using conditional logistic regression, based on study-specific tenths of calculated free testosterone concentration.Results and limitationsMen in the lowest tenth of free testosterone concentration had a lower risk of overall prostate cancer (OR=0.77, 95% confidence interval [CI] 0.69-0.86; p

Published
2018

4. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

Author

Travis, Ruth C, Appleby, Paul N, Martin, Richard M, Holly, Jeff MP, Albanes, Demetrius, Black, Amanda, Bueno-de-Mesquita, HB As, Chan, June M, Chen, Chu, Chirlaque, Maria-Dolores, Cook, Michael B, Deschasaux, Mélanie, Donovan, Jenny L, Ferrucci, Luigi, Galan, Pilar, Giles, Graham G, Giovannucci, Edward L, Gunter, Marc J, Habel, Laurel A, Hamdy, Freddie C, Helzlsouer, Kathy J, Hercberg, Serge, Hoover, Robert N, Janssen, Joseph AMJL, Kaaks, Rudolf, Kubo, Tatsuhiko, Le Marchand, Loic, Metter, E Jeffrey, Mikami, Kazuya, Morris, Joan K, Neal, David E, Neuhouser, Marian L, Ozasa, Kotaro, Palli, Domenico, Platz, Elizabeth A, Pollak, Michael, Price, Alison J, Roobol, Monique J, Schaefer, Catherine, Schenk, Jeannette M, Severi, Gianluca, Stampfer, Meir J, Stattin, Pär, Tamakoshi, Akiko, Tangen, Catherine M, Touvier, Mathilde, Wald, Nicholas J, Weiss, Noel S, Ziegler, Regina G, Key, Timothy J, and Allen, Naomi E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Cancer, Urologic Diseases, Aged, Humans, Insulin-Like Growth Factor I, Male, Middle Aged, Prostatic Neoplasms, Risk Factors, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from 17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. After mutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300. ©2016 AACR.

Published
2016

5. Supplementary Materials and Methods from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

Author

Travis, Ruth C., primary, Appleby, Paul N., primary, Martin, Richard M., primary, Holly, Jeff M.P., primary, Albanes, Demetrius, primary, Black, Amanda, primary, Bueno-de-Mesquita, H. Bas, primary, Chan, June M., primary, Chen, Chu, primary, Chirlaque, Maria-Dolores, primary, Cook, Michael B., primary, Deschasaux, Mélanie, primary, Donovan, Jenny L., primary, Ferrucci, Luigi, primary, Galan, Pilar, primary, Giles, Graham G., primary, Giovannucci, Edward L., primary, Gunter, Marc J., primary, Habel, Laurel A., primary, Hamdy, Freddie C., primary, Helzlsouer, Kathy J., primary, Hercberg, Serge, primary, Hoover, Robert N., primary, Janssen, Joseph A.M.J.L., primary, Kaaks, Rudolf, primary, Kubo, Tatsuhiko, primary, Le Marchand, Loic, primary, Metter, E. Jeffrey, primary, Mikami, Kazuya, primary, Morris, Joan K., primary, Neal, David E., primary, Neuhouser, Marian L., primary, Ozasa, Kotaro, primary, Palli, Domenico, primary, Platz, Elizabeth A., primary, Pollak, Michael N., primary, Price, Alison J., primary, Roobol, Monique J., primary, Schaefer, Catherine, primary, Schenk, Jeannette M., primary, Severi, Gianluca, primary, Stampfer, Meir J., primary, Stattin, Pär, primary, Tamakoshi, Akiko, primary, Tangen, Catherine M., primary, Touvier, Mathilde, primary, Wald, Nicholas J., primary, Weiss, Noel S., primary, Ziegler, Regina G., primary, Key, Timothy J., primary, and Allen, Naomi E., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure Legends from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

Author

Travis, Ruth C., primary, Appleby, Paul N., primary, Martin, Richard M., primary, Holly, Jeff M.P., primary, Albanes, Demetrius, primary, Black, Amanda, primary, Bueno-de-Mesquita, H. Bas, primary, Chan, June M., primary, Chen, Chu, primary, Chirlaque, Maria-Dolores, primary, Cook, Michael B., primary, Deschasaux, Mélanie, primary, Donovan, Jenny L., primary, Ferrucci, Luigi, primary, Galan, Pilar, primary, Giles, Graham G., primary, Giovannucci, Edward L., primary, Gunter, Marc J., primary, Habel, Laurel A., primary, Hamdy, Freddie C., primary, Helzlsouer, Kathy J., primary, Hercberg, Serge, primary, Hoover, Robert N., primary, Janssen, Joseph A.M.J.L., primary, Kaaks, Rudolf, primary, Kubo, Tatsuhiko, primary, Le Marchand, Loic, primary, Metter, E. Jeffrey, primary, Mikami, Kazuya, primary, Morris, Joan K., primary, Neal, David E., primary, Neuhouser, Marian L., primary, Ozasa, Kotaro, primary, Palli, Domenico, primary, Platz, Elizabeth A., primary, Pollak, Michael N., primary, Price, Alison J., primary, Roobol, Monique J., primary, Schaefer, Catherine, primary, Schenk, Jeannette M., primary, Severi, Gianluca, primary, Stampfer, Meir J., primary, Stattin, Pär, primary, Tamakoshi, Akiko, primary, Tangen, Catherine M., primary, Touvier, Mathilde, primary, Wald, Nicholas J., primary, Weiss, Noel S., primary, Ziegler, Regina G., primary, Key, Timothy J., primary, and Allen, Naomi E., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Tables 1 through 8 and Supplementary Figures 1 through 15 from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

Author

Travis, Ruth C., primary, Appleby, Paul N., primary, Martin, Richard M., primary, Holly, Jeff M.P., primary, Albanes, Demetrius, primary, Black, Amanda, primary, Bueno-de-Mesquita, H. Bas, primary, Chan, June M., primary, Chen, Chu, primary, Chirlaque, Maria-Dolores, primary, Cook, Michael B., primary, Deschasaux, Mélanie, primary, Donovan, Jenny L., primary, Ferrucci, Luigi, primary, Galan, Pilar, primary, Giles, Graham G., primary, Giovannucci, Edward L., primary, Gunter, Marc J., primary, Habel, Laurel A., primary, Hamdy, Freddie C., primary, Helzlsouer, Kathy J., primary, Hercberg, Serge, primary, Hoover, Robert N., primary, Janssen, Joseph A.M.J.L., primary, Kaaks, Rudolf, primary, Kubo, Tatsuhiko, primary, Le Marchand, Loic, primary, Metter, E. Jeffrey, primary, Mikami, Kazuya, primary, Morris, Joan K., primary, Neal, David E., primary, Neuhouser, Marian L., primary, Ozasa, Kotaro, primary, Palli, Domenico, primary, Platz, Elizabeth A., primary, Pollak, Michael N., primary, Price, Alison J., primary, Roobol, Monique J., primary, Schaefer, Catherine, primary, Schenk, Jeannette M., primary, Severi, Gianluca, primary, Stampfer, Meir J., primary, Stattin, Pär, primary, Tamakoshi, Akiko, primary, Tangen, Catherine M., primary, Touvier, Mathilde, primary, Wald, Nicholas J., primary, Weiss, Noel S., primary, Ziegler, Regina G., primary, Key, Timothy J., primary, and Allen, Naomi E., primary

Published
2023
Full Text
View/download PDF

8. Data from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

Author

Travis, Ruth C., primary, Appleby, Paul N., primary, Martin, Richard M., primary, Holly, Jeff M.P., primary, Albanes, Demetrius, primary, Black, Amanda, primary, Bueno-de-Mesquita, H. Bas, primary, Chan, June M., primary, Chen, Chu, primary, Chirlaque, Maria-Dolores, primary, Cook, Michael B., primary, Deschasaux, Mélanie, primary, Donovan, Jenny L., primary, Ferrucci, Luigi, primary, Galan, Pilar, primary, Giles, Graham G., primary, Giovannucci, Edward L., primary, Gunter, Marc J., primary, Habel, Laurel A., primary, Hamdy, Freddie C., primary, Helzlsouer, Kathy J., primary, Hercberg, Serge, primary, Hoover, Robert N., primary, Janssen, Joseph A.M.J.L., primary, Kaaks, Rudolf, primary, Kubo, Tatsuhiko, primary, Le Marchand, Loic, primary, Metter, E. Jeffrey, primary, Mikami, Kazuya, primary, Morris, Joan K., primary, Neal, David E., primary, Neuhouser, Marian L., primary, Ozasa, Kotaro, primary, Palli, Domenico, primary, Platz, Elizabeth A., primary, Pollak, Michael N., primary, Price, Alison J., primary, Roobol, Monique J., primary, Schaefer, Catherine, primary, Schenk, Jeannette M., primary, Severi, Gianluca, primary, Stampfer, Meir J., primary, Stattin, Pär, primary, Tamakoshi, Akiko, primary, Tangen, Catherine M., primary, Touvier, Mathilde, primary, Wald, Nicholas J., primary, Weiss, Noel S., primary, Ziegler, Regina G., primary, Key, Timothy J., primary, and Allen, Naomi E., primary

Published
2023
Full Text
View/download PDF

9. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer : a collaborative analysis of 20 prospective studies and Mendelian randomization analysis

Author

Watts, Eleanor L., Perez-Cornago, Aurora, Fensom, Georgina K., Smith-Byrne, Karl, Noor, Urwah, Andrews, Colm D., Gunter, Marc J., Holmes, Michael V., Martin, Richard M., Tsilidis, Konstantinos K., Albanes, Demetrius, Barricarte, Aurelio, Bueno-De-Mesquita, H. Bas, Cohn, Barbara A., Deschasaux-Tanguy, Melanie, Dimou, Niki L., Ferrucci, Luigi, Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward L., Haiman, Christopher A., Hankey, Graham J., Holly, Jeffrey M. P., Huang, Jiaqi, Huang, Wen-Yi, Hurwitz, Lauren M., Kaaks, Rudolf, Kubo, Tatsuhiko, Le Marchand, Loic, Macinnis, Robert J., Männistö, Satu, Metter, E. Jeffrey, Mikami, Kazuya, Mucci, Lorelei A., Olsen, Anja W., Ozasa, Kotaro, Palli, Domenico, Penney, Kathryn L., Platz, Elizabeth A., Pollak, Michael N., Roobol, Monique J., Schaefer, Catherine A., Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Tsai, Chiaojung Jillian, Touvier, Mathilde, Van Den Eeden, Stephen K., Weiderpass, Elisabete, Weinstein, Stephanie J., Wilkens, Lynne R., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., Travis, Ruth C., The PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS, Watts, Eleanor L., Perez-Cornago, Aurora, Fensom, Georgina K., Smith-Byrne, Karl, Noor, Urwah, Andrews, Colm D., Gunter, Marc J., Holmes, Michael V., Martin, Richard M., Tsilidis, Konstantinos K., Albanes, Demetrius, Barricarte, Aurelio, Bueno-De-Mesquita, H. Bas, Cohn, Barbara A., Deschasaux-Tanguy, Melanie, Dimou, Niki L., Ferrucci, Luigi, Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward L., Haiman, Christopher A., Hankey, Graham J., Holly, Jeffrey M. P., Huang, Jiaqi, Huang, Wen-Yi, Hurwitz, Lauren M., Kaaks, Rudolf, Kubo, Tatsuhiko, Le Marchand, Loic, Macinnis, Robert J., Männistö, Satu, Metter, E. Jeffrey, Mikami, Kazuya, Mucci, Lorelei A., Olsen, Anja W., Ozasa, Kotaro, Palli, Domenico, Penney, Kathryn L., Platz, Elizabeth A., Pollak, Michael N., Roobol, Monique J., Schaefer, Catherine A., Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Tsai, Chiaojung Jillian, Touvier, Mathilde, Van Den Eeden, Stephen K., Weiderpass, Elisabete, Weinstein, Stephanie J., Wilkens, Lynne R., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., Travis, Ruth C., and The PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS

Abstract

Background: Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. Methods: Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. Results: In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. Conclusions: These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.

Published
2023
Full Text
View/download PDF

10. Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection

Author

Naya, Yoshio, Mikami, Kazuya, Takaha, Natsuki, Inoue, Yuuta, Fujihara, Atsuko, Kanazawa, Motohiro, Nakanishi, Hiroyuki, Miyashita, Hiroaki, and Ukimura, Osamu

Published
2018
Full Text
View/download PDF

11. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer:a collaborative analysis of 20 prospective studies and Mendelian randomization analysis

Author

Watts, Eleanor L., Perez-Cornago, Aurora, Fensom, Georgina K., Smith-Byrne, Karl, Noor, Urwah, Andrews, Colm D., Gunter, Marc J., Holmes, Michael V., Martin, Richard M., Tsilidis, Konstantinos K., Albanes, Demetrius, Barricarte, Aurelio, Bueno-De-Mesquita, H. Bas, Cohn, Barbara A., Deschasaux-Tanguy, Melanie, Dimou, Niki L., Ferrucci, Luigi, Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward L., Haiman, Christopher A., Hankey, Graham J., Holly, Jeffrey M. P., Huang, Jiaqi, Huang, Wen-Yi, Hurwitz, Lauren M., Kaaks, Rudolf, Kubo, Tatsuhiko, Le Marchand, Loic, Macinnis, Robert J., Männistö, Satu, Metter, E. Jeffrey, Mikami, Kazuya, Mucci, Lorelei A., Olsen, Anja W., Ozasa, Kotaro, Palli, Domenico, Penney, Kathryn L., Platz, Elizabeth A., Pollak, Michael N., Roobol, Monique J., Schaefer, Catherine A., Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Tsai, Chiaojung Jillian, Touvier, Mathilde, Van Den Eeden, Stephen K., Weiderpass, Elisabete, Weinstein, Stephanie J., Wilkens, Lynne R., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., Travis, Ruth C., The PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS, and consortium, The PRACTICAL

Subjects
Cancer och onkologi, prospective analysis, Epidemiology, General Medicine, prostate cancer, aggressive prostate cancer, Cancer and Oncology, Mendelian randomization, international consortia, Insulin-like growth factor-I, ICEP, Bristol Population Health Science Institute
Abstract

Background Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. Methods Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. Results In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. Conclusions These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.

Published
2022

12. Circulating free testosterone and risk of aggressive prostate cancer : Prospective and Mendelian randomisation analyses in international consortia

Author

Watts, Eleanor L., Perez-Cornago, Aurora, Fensom, Georgina K., Smith-Byrne, Karl, Noor, Urwah, Andrews, Colm D., Gunter, Marc J., Holmes, Michael, V, Martin, Richard M., Tsilidis, Konstantinos K., Albanes, Demetrius, Barricarte, Aurelio, Bueno-de-Mesquita, Bas, Chen, Chu, Cohn, Barbara A., Dimou, Niki L., Ferrucci, Luigi, Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward L., Goodman, Gary E., Haiman, Christopher A., Hankey, Graeme J., Huang, Jiaqi, Huang, Wen-Yi, Hurwitz, Lauren M., Kaaks, Rudolf, Knekt, Paul, Kubo, Tatsuhiko, Langseth, Hilde, Laughlin, Gail, Le Marchand, Loic, Luostarinen, Tapio, MacInnis, Robert J., Maenpaa, Hanna O., Mannisto, Satu, Metter, Jeffrey E., Mikami, Kazuya, Mucci, Lorelei A., Olsen, Anja W., Ozasa, Kotaro, Palli, Domenico, Penney, Kathryn L., Platz, Elizabeth A., Rissanen, Harri, Sawada, Norie, Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Tsai, Chiaojung Jillian, Tsugane, Shoichiro, Vatten, Lars, Weiderpass, Elisabete, Weinstein, Stephanie J., Wilkens, Lynne R., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., Travis, Ruth C., Watts, Eleanor L., Perez-Cornago, Aurora, Fensom, Georgina K., Smith-Byrne, Karl, Noor, Urwah, Andrews, Colm D., Gunter, Marc J., Holmes, Michael, V, Martin, Richard M., Tsilidis, Konstantinos K., Albanes, Demetrius, Barricarte, Aurelio, Bueno-de-Mesquita, Bas, Chen, Chu, Cohn, Barbara A., Dimou, Niki L., Ferrucci, Luigi, Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward L., Goodman, Gary E., Haiman, Christopher A., Hankey, Graeme J., Huang, Jiaqi, Huang, Wen-Yi, Hurwitz, Lauren M., Kaaks, Rudolf, Knekt, Paul, Kubo, Tatsuhiko, Langseth, Hilde, Laughlin, Gail, Le Marchand, Loic, Luostarinen, Tapio, MacInnis, Robert J., Maenpaa, Hanna O., Mannisto, Satu, Metter, Jeffrey E., Mikami, Kazuya, Mucci, Lorelei A., Olsen, Anja W., Ozasa, Kotaro, Palli, Domenico, Penney, Kathryn L., Platz, Elizabeth A., Rissanen, Harri, Sawada, Norie, Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Tsai, Chiaojung Jillian, Tsugane, Shoichiro, Vatten, Lars, Weiderpass, Elisabete, Weinstein, Stephanie J., Wilkens, Lynne R., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., and Travis, Ruth C.

Abstract

Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. In blood-based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse-variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08-1.40). In blood-based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged <60 years 1.14, CI = 1.02-1.28; P-het = .0003: inverse association for older ages). Associations for free testosterone were positive for overall prostate cancer (MR: 1.20, 1.08-1.34; blood-based: 1.03, 1.01-1.05) and early-onset prostate cancer (MR: 1.37, 1.09-1.73; blood-based: 1.08, 0.98-1.19). SHBG and total testosterone were inversely associated with overall prostate cancer in blood-based analyses, with null associations in MR analysis. Our results support free testosterone, rather than total testosterone, in the development of prostate cancer, including aggressive subgroups.

Published
2022
Full Text
View/download PDF

13. THE COMPARISON ONE IMMEDIATE POSTOPERATIVE INTRAVESICAL CHEMOTHERAPY WITH SHORT-TERM ADJUVANT INTRAVESICAL CHEMOTHERAPY AFTER TURBT IN LOW- AND INTERMEDIATE RECURRENT RISK OF NON-MUSCLE-INVASIVE BLADDER CANCER- A RANDOMIZED PROSPECTIVE STUDY IN JAPAN.: MP13-08

Author

Naya, Yoshio, Shiraishi, Takumi, Oishi, Masakatsu, Ueda, Takashi, Nakanshi, Hiroyuki, Naitoh, Yasuyuki, Nakamura, Terukazu, Hongo, Fumiya, Kamoi, Kazumi, Okihara, Koji, Mikami, Kazuya, Iwata, Tsuyoshi, and Ukimura, Osamu

Published
2016
Full Text
View/download PDF

14. Television Viewing Time and Breast Cancer Incidence or Japanese Premenopausal and Postmenopausal Women : The JACC Study

Author

Cao, Jinhong, Eshak, Ehab Salah, Liu, Keyang, Muraki, Isar, Cui, Renzhe, Iso, Hiroyasu, Tamakoshi, Akiko, Mori, Mitsuru, Kaneko, Yoshihiro, Tsuji, Ichiro, Nakamura, Yosikazu, Yamagishi, Kazumasa, Mikami, Haruo, Kurosawa, Michiko, Hoshiyama, Yoshiharu, Tanabe, Naohito, Tamakoshi, Koji, Wakai, Kenji, Tokudome, Shinkan, Suzuki, Koji, Hashimoto, Shuji, Yatsuya, Hiroshi, Kikuchi, Shogo, Wada, Yasuhiko, Kawamura, Takashi, Watanabe, Yoshiyuki, Ozasa, Kotaro, Mikami, Kazuya, Date, Chigusa, Sakata, Kiyomi, Yoshimura, Takesumi, Fujino, Yoshihisa, Shibata, Akira, Okamoto, Naoyuki, Shio, Hideo, and Kurozawa, Yoichi

Subjects
Adult, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Time Factors, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Japan, medicine, Humans, Prospective Studies, Prospective cohort study, Health Education, Body mass index, Aged, Proportional Hazards Models, Postmenopausal women, Obstetrics, business.industry, Incidence (epidemiology), Incidence, Hazard ratio, Television viewing time, Middle Aged, medicine.disease, Confidence interval, Postmenopause, 030104 developmental biology, Premenopause, Oncology, 030220 oncology & carcinogenesis, Women's Health, Original Article, Female, Television, Postmenopausal, Self Report, Breast neoplasms, business, Cohort study
Abstract

Purpose The evidence on effects of TV viewing time among premenopausal and postmenopausal women for breast cancer risk remains controversial and limited. Materials and Methods A prospective study encompassing 33,276 (17,568 premenopausal, and 15,708 postmenopausal) women aged 40-79 years in whom TV viewing time, menstrual, and reproductive histories were determined by a self-administered questionnaire. The follow-up was from 1988 to 2009 and hazard ratios (HRs) with 95% confidence intervals (as) of breast cancer incidence were calculated for longer TV viewing time in reference to shorter TV viewing time by Cox proportional hazard models. Results During 16.8-year median follow-up, we found positive associations between TV viewing time and breast cancer incidence with a borderline significant trend among total women and a significant trend among postmenopausal women. Among total women, the multivariable HRs (95% Cis) for risk of breast cancer in reference to < 1.5 hr/day of TV viewing time were 0.89 (0.59-1.34) for 1.5 to < 3.0 hr/day, 1.19 (0.82-1.74) for 3.0 to < 4.5 hr/day, and 1.45 (0.91-2.32) for >= 4.5 hr/day (p for trend=0.053) and among postmenopausal women, the corresponding risk estimates were 1.10 (0.42-2.88), 2.54 (1.11-5.80), and 2.37 (0.926.10) (p for trend=0.009), respectively. Conclusion Prolonged TV viewing time was associated with increased risk of breast cancer, especially among postmenopausal women.

Published
2019

15. Self-Reported Eczema in Relation with Mortality from Cardiovascular Disease in Japanese: the Japan Collaborative Cohort Study

Author

Nishida, Yoko, Kubota, Yasuhiko, Iso, Hiroyasu, Tamakoshi, Akiko, Mori, Mitsuru, Kaneko, Yoshihiro, Tsuji, Ichiro, Nakamura, Yosikazu, Yamagishi, Kazumasa, Mikami, Haruo, Kurosawa, Michiko, Hoshiyama, Yoshiharu, Tanabe, Naohito, Tamakoshi, Koji, Wakai, Kenji, Ando, Masahiko, Suzuki, Koji, Hashimoto, Shuji, Yatsuya, Hiroshi, Kikuchi, Shogo, Wada, Yasuhiko, Kawamura, Takashi, Watanabe, Yoshiyuki, Ozasa, Kotaro, Mikami, Kazuya, Date, Chigusa, Sakata, Kiyomi, Kurozawa, Yoichi, Fujino, Yoshihisa, and Shibata, Akira

Subjects
Adult, Male, medicine.medical_specialty, Population, Eczema, Disease, 030204 cardiovascular system & hematology, Systemic inflammation, 03 medical and health sciences, 0302 clinical medicine, Japan, Risk Factors, Internal medicine, Surveys and Questionnaires, Internal Medicine, Risk of mortality, Medicine, Humans, cardiovascular diseases, Prospective Studies, education, Stroke, Life Style, Population-based study, Aged, education.field_of_study, business.industry, Incidence, Biochemistry (medical), Confounding, Middle Aged, medicine.disease, Cardiovascular disease, Atherosclerosis, Prognosis, Survival Rate, CHD, Cardiovascular Diseases, Heart failure, Original Article, Female, Self Report, medicine.symptom, Cardiology and Cardiovascular Medicine, business, 030217 neurology & neurosurgery, Cohort study, Follow-Up Studies
Abstract

Aim: Previous studies suggested a positive association between eczema and cardiovascular disease (CVD), probably through enhanced systemic inflammation. However, several studies reported null findings about eczema and CVD, so the evidence is still controversial. Methods: We asked 85,099 participants (35,489 men and 49,610 women), aged 40 to 79 years, without a history of CVD or cancer at baseline between 1988 and 1990, to complete a lifestyle questionnaire, including information eczema frequency (seldom, sometimes or often). Results: During the 6,389,818 person-years of follow-up, there were 1,174 deaths from coronary heart disease (CHD), 979 from heart failure, 366 from cardiac arrhythmia, 2,454 from total stroke, 1,357 from ischemic stroke, 1,013 from hemorrhagic stroke, and 201 from aortic aneurysm or dissection. The multivariable-adjusted model showed that individuals who “sometimes” or “often” had eczema had 0.82 (95%confidence interval (CI): 0.69–0.97) or 1.26 (95%CI: 1.01–1.56) times the risk of mortality from CHD, respectively, compared to those who “seldom” did. Individuals who “often” had 1.30 (95%CI: 1.05–1.61) times the risk of mortality from CHD, compared to those who “seldom or sometimes” did. There was no association of eczema with mortality from other CVD, or no interaction between eczema and sex or age, in relation to any CVD mortality risk. Conclusions: Self-reported frequent eczema was associated with increased risk of mortality from CHD, but not other major CVD, in a Japanese general population. Since steroid usage was not considered, future studies should include it as a potential confounding factor.

Published
2019

16. Clinical characteristics and oncological outcomes of testicular cancer patients registered in 2005 and 2008: The first large-scale study from the Cancer Registration Committee of the Japanese Urological Association

Author

Miki, Tsuneharu, Kamoi, Kazumi, Fujimoto, Hiroyuki, Kanayama, Hiro-omi, Ohyama, Chikara, Suzuki, Kazuhiro, Nishiyama, Hiroyuki, Eto, Masatoshi, Naito, Seiji, Fukumori, Tomoharu, Kubota, Yoshinobu, Takahashi, Satoru, Mikami, Kazuya, and Homma, Yukio

Published
2014
Full Text
View/download PDF

35. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies

Author

Watts, Eleanor L., Perez-Cornago, Aurora, Appleby, Paul N., Albanes, Demetrius, Ardanaz, Eva, Black, Amanda, Bueno-de-Mesquita, H. Bas, Chan, June M., Chen, Chu, Chubb, S. A. Paul, Cook, Michael B., Deschasaux, Melanie, Donovan, Jenny L., English, Dallas R., Flicker, Leon, Freedman, Neal D., Galan, Pilar, Giles, Graham G., Giovannucci, Edward L., Gunter, Marc J., Habel, Laurel A., Häggström, Christel, Haiman, Christopher, Hamdy, Freddie C., Hercberg, Serge, Holly, Jeff M., Huang, Jiaqi, Huang, Wen-Yi, Johansson, Mattias, Kaaks, Rudolf, Kubo, Tatsuhiko, Lane, J. Athene, Layne, Tracy M., Le Marchand, Loic, Martin, Richard M., Metter, E. Jeffrey, Mikami, Kazuya, Milne, Roger L., Morris, Howard A., Mucci, Lorelei A., Neal, David E., Neuhouser, Marian L., Oliver, Steven E., Overvad, Kim, Ozasa, Kotaro, Pala, Valeria, Pernar, Claire H., Pollak, Michael, Rowlands, Mari-Anne, Schaefer, Catherine A., Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Touvier, Mathilde, Trichopoulou, Antonia, Tsilidis, Konstantinos K., Van Den Eeden, Stephen K., Weinstein, Stephanie J., Wilkens, Lynne, Yeap, Bu B., Key, Timothy J., Allen, Naomi E., Travis, Ruth C., Watts, Eleanor L., Perez-Cornago, Aurora, Appleby, Paul N., Albanes, Demetrius, Ardanaz, Eva, Black, Amanda, Bueno-de-Mesquita, H. Bas, Chan, June M., Chen, Chu, Chubb, S. A. Paul, Cook, Michael B., Deschasaux, Melanie, Donovan, Jenny L., English, Dallas R., Flicker, Leon, Freedman, Neal D., Galan, Pilar, Giles, Graham G., Giovannucci, Edward L., Gunter, Marc J., Habel, Laurel A., Häggström, Christel, Haiman, Christopher, Hamdy, Freddie C., Hercberg, Serge, Holly, Jeff M., Huang, Jiaqi, Huang, Wen-Yi, Johansson, Mattias, Kaaks, Rudolf, Kubo, Tatsuhiko, Lane, J. Athene, Layne, Tracy M., Le Marchand, Loic, Martin, Richard M., Metter, E. Jeffrey, Mikami, Kazuya, Milne, Roger L., Morris, Howard A., Mucci, Lorelei A., Neal, David E., Neuhouser, Marian L., Oliver, Steven E., Overvad, Kim, Ozasa, Kotaro, Pala, Valeria, Pernar, Claire H., Pollak, Michael, Rowlands, Mari-Anne, Schaefer, Catherine A., Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Touvier, Mathilde, Trichopoulou, Antonia, Tsilidis, Konstantinos K., Van Den Eeden, Stephen K., Weinstein, Stephanie J., Wilkens, Lynne, Yeap, Bu B., Key, Timothy J., Allen, Naomi E., and Travis, Ruth C.

Abstract

Insulin-like growth factors (IGFs) and insulin-like growth factor binding proteins (IGFBPs) have been implicated in the aetiology of several cancers. To better understand whether anthropometric, behavioural and sociodemographic factors may play a role in cancer risk via IGF signalling, we examined the cross-sectional associations of these exposures with circulating concentrations of IGFs (IGF-I and IGF-II) and IGFBPs (IGFBP-1, IGFBP-2 and IGFBP-3). The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset includes individual participant data from 16,024 male controls (i.e. without prostate cancer) aged 22-89 years from 22 prospective studies. Geometric means of protein concentrations were estimated using analysis of variance, adjusted for relevant covariates. Older age was associated with higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations of IGF-I, IGF-II and IGFBP-3. Higher body mass index was associated with lower concentrations of IGFBP-1 and IGFBP-2. Taller height was associated with higher concentrations of IGF-I and IGFBP-3 and lower concentrations of IGFBP-1. Smokers had higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations of IGFBP-3 than nonsmokers. Higher alcohol consumption was associated with higher concentrations of IGF-II and lower concentrations of IGF-I and IGFBP-2. African Americans had lower concentrations of IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 and Hispanics had lower IGF-I, IGF-II and IGFBP-3 than non-Hispanic whites. These findings indicate that a range of anthropometric, behavioural and sociodemographic factors are associated with circulating concentrations of IGFs and IGFBPs in men, which will lead to a greater understanding of the mechanisms through which these factors influence cancer risk.

Published
2019
Full Text
View/download PDF

36. Sleep duration and risk of breast cancer : The JACC Study

Author

Cao, Jinhong, Eshak, Ehab S., Liu, Keyang, 1000070731561, Muraki, Isao, 1000040375514, Cui, Renzhe, 1000050223053, Iso, Hiroyasu, 1000090236737, Tamakoshi, Akiko, Mori, Mitsuru, Kaneko, Yoshihiro, Tsuji, Ichiro, Nakamura, Yosikazu, Yamagishi, Kazumasa, Mikami, Haruo, Kurosawa, Michiko, Hoshiyama, Yoshiharu, Tanabe, Naohito, Tamakoshi, Koji, Wakai, Kenji, Tokudome, Shinkan, Suzuki, Koji, Hashimoto, Shuji, Yatsuya, Hiroshi, Kikuchi, Shogo, Wada, Yasuhiko, Kawamura, Takashi, Watanabe, Yoshiyuki, Ozasa, Kotaro, Mikami, Kazuya, Date, Chigusa, Sakata, Kiyomi, Kurozawa, Yoichi, Yoshimura, Takesumi, Fujino, Yoshihisa, Shibata, Akira, Okamoto, Naoyuki, Shio, Hideo, Cao, Jinhong, Eshak, Ehab S., Liu, Keyang, 1000070731561, Muraki, Isao, 1000040375514, Cui, Renzhe, 1000050223053, Iso, Hiroyasu, 1000090236737, Tamakoshi, Akiko, Mori, Mitsuru, Kaneko, Yoshihiro, Tsuji, Ichiro, Nakamura, Yosikazu, Yamagishi, Kazumasa, Mikami, Haruo, Kurosawa, Michiko, Hoshiyama, Yoshiharu, Tanabe, Naohito, Tamakoshi, Koji, Wakai, Kenji, Tokudome, Shinkan, Suzuki, Koji, Hashimoto, Shuji, Yatsuya, Hiroshi, Kikuchi, Shogo, Wada, Yasuhiko, Kawamura, Takashi, Watanabe, Yoshiyuki, Ozasa, Kotaro, Mikami, Kazuya, Date, Chigusa, Sakata, Kiyomi, Kurozawa, Yoichi, Yoshimura, Takesumi, Fujino, Yoshihisa, Shibata, Akira, Okamoto, Naoyuki, and Shio, Hideo

Abstract

PurposeThe evidence on beneficial or adverse effects of sleep duration on risk of breast cancer remains controversial and limited, especially in Asia.MethodsA prospective study of 34,350 women aged 40-79years in whom sleep duration, and menstrual and reproductive histories were determined by a self-administered questionnaire. The follow-up period was from 1988 to 2009, and hazard ratios (HRs) with 95% confidence intervals (CIs) of breast cancer incidence were calculated for shorter sleep duration in reference to sleep duration of 8h/day by Cox proportional hazard models.ResultsDuring 19.2-year median follow-up (236 cases), we found a significant inverse association between sleep duration and risk of breast cancer, especially among postmenopausal women and women with low parity (nulliparous and women with <3 children); the multivariable HRs (95% CIs) among postmenopausal women who reported 7h/day and 6h/day of sleep in reference to 8h/day were 1.49 (0.81-2.76) and 1.98 (1.08-3.70) (P for trend=0.028), respectively, and the corresponding values among women with low parity were 1.50 (0.96-2.35) and 1.76 (1.01-2.79) (P for trend=0.018).ConclusionsShort sleep duration was associated with increased risk of incident breast cancer, especially among postmenopausal women and women with low parity.

Published
2019

38. Dairy products and the risk of developing prostate cancer: A large‐scale cohort study (JACC Study) in Japan.

Author

Mikami, Kazuya, Ozasa, Kotaro, Miki, Tsuneharu, Watanabe, Yoshiyuki, Mori, Mitsuru, Kubo, Tatsuhiko, Suzuki, Koji, Wakai, Kenji, Nakao, Masahiro, and Tamakoshi, Akiko

Subjects
*DAIRY products, *PROSTATE cancer, *PROPORTIONAL hazards models, *COHORT analysis, *BODY mass index, *JAPANESE people
Abstract

Dairy products have been indicated as a risk factor for prostate cancer. However, only a few epidemiological studies have reported dairy products as being a risk factor for prostate cancer in Japan, reporting contradictory results. We therefore investigated the association between the intake of dairy products and the occurrence of prostate cancer through a large‐scale cohort study. The Japan Collaborative Cohort study analyzed approximately 110,000 residents from various Japanese districts who participated in our questionnaire survey during 1988–1990. The subjects of the present study were 26,464 men (age range: 40–79 years) from 24 districts wherein cancer incidence was reported. Their clinical course was followed up until 2009. Hazard ratios (HRs) were calculated using Cox's proportional hazards model, adjusted for age, survey area, family history of prostate cancer, body mass index, and total energy intake. For diet, we calculated the HRs associated with intermediate and high consumption of dairy products and compared them with those associated with low consumption. There were 412 cases of prostate cancer in the survey population. As dairy products, milk, yogurt, cheese, and butter were evaluated. Among them, milk consumption was associated with a significant risk (HR = 1.37, p = 0.009) and a dose‐dependent response (p for trend = 0.009) adjusted for age and family history of prostate cancer, stratified by area. Milk and yogurt consumption showed a significantly positive risk and a dose–response relationship adjusted for age, family history of prostate cancer, body mass index, and total energy intake, stratified by area. In summary, a high intake of dairy products such as milk increased the risk of developing prostate cancer in Japanese men. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study

Author

KOJIMA, MUNEKADO, KAMOI, KAZUMI, UKIMURA, OSAMU, FUJITO, AKIRA, NAKAO, MASAHIRO, TANAKA, SHIGEKI, MIYASHITA, HIROAKI, IWAMOTO, NORIYUKI, OHE, HIROSHI, KITAMORI, TOMOHITO, DATE, SEIKI, KITAMURA, KOJI, ARAKI, HIROTAKA, AOKI, TADASHI, IMADA, NAOKI, TAKADA, HITOSHI, IMAIDE, YOICHIROH, MIKAMI, KAZUYA, UCHIDA, MUTSUMI, SAITOH, MASAHITO, and MIKI, TSUNEHARU

Published
2002

41. Low Free Testosterone and Prostate Cancer Risk : A Collaborative Analysis of 20 Prospective Studies

Author

Watts, Eleanor L., Appleby, Paul N., Perez-Cornago, Aurora, Bueno-de-Mesquita, H. Bas, Chan, June M., Chen, Chu, Cohn, Barbara A., Cook, Michael B., Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward, Gislefoss, Randi E., Hankey, Graeme J., Kaaks, Rudolf, Knekt, Paul, Kolonel, Laurence N., Kubo, Tatsuhiko, Le Marchand, Loic, Luben, Robert N., Luostarinen, Tapio, Mannisto, Satu, Metter, E. Jeffrey, Mikami, Kazuya, Milne, Roger L., Ozasa, Kotaro, Platz, Elizabeth A., Quiros, J. Ramon, Rissanen, Harri, Sawada, Norie, Stampfer, Meir, Stanczyk, Frank Z., Stattin, Pär, Tamakoshi, Akiko, Tangen, Catherine M., Thompson, Ian M., Tsilidis, Konstantinos K., Tsugane, Shoichiro, Ursin, Giske, Vatten, Lars, Weiss, Noel S., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., and Travis, Ruth C.

Subjects
Adult, Male, Urologic Diseases, Aging, Time Factors, Epidemiology, Clinical Sciences, FLOATING ABSOLUTE RISK, Down-Regulation, Risk Assessment, Pooled analysis, SEX STEROID ASSAYS, Risk Factors, Clinical Research, Urologi och njurmedicin, Humans, 2.1 Biological and endogenous factors, Urology and Nephrology, Sex hormones, Testosterone, Prospective Studies, Aetiology, Aged, Cancer, PREVENTION TRIAL, Science & Technology, Prostate cancer, Prevention, ANDROGEN RECEPTOR, Prostatic Neoplasms, MEN, 1103 Clinical Sciences, MASS-SPECTROMETRY, Androgens Pooled analysis, Middle Aged, Protective Factors, Urology & Nephrology, SERUM TESTOSTERONE, Case-Control Studies, Androgens, FINASTERIDE, CLINICAL-IMPLICATIONS, HORMONES, Neoplasm Grading, Life Sciences & Biomedicine, Prospective studies, Biomarkers
Abstract

Background Experimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting. Objective To examine whether men with low concentrations of circulating free testosterone have a reduced risk of prostate cancer. Design, setting, and participants Analysis of individual participant data from 20 prospective studies including 6933 prostate cancer cases, diagnosed on average 6.8 yr after blood collection, and 12 088 controls in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. Outcome measurements and statistical analysis Odds ratios (ORs) of incident overall prostate cancer and subtypes by stage and grade, using conditional logistic regression, based on study-specific tenths of calculated free testosterone concentration. Results and limitations Men in the lowest tenth of free testosterone concentration had a lower risk of overall prostate cancer (OR = 0.77, 95% confidence interval [CI] 0.69–0.86; p < 0.001) compared with men with higher concentrations (2nd–10th tenths of the distribution). Heterogeneity was present by tumour grade (phet = 0.01), with a lower risk of low-grade disease (OR = 0.76, 95% CI 0.67–0.88) and a nonsignificantly higher risk of high-grade disease (OR = 1.56, 95% CI 0.95–2.57). There was no evidence of heterogeneity by tumour stage. The observational design is a limitation. Conclusions Men with low circulating free testosterone may have a lower risk of overall prostate cancer; this may be due to a direct biological effect, or detection bias. Further research is needed to explore the apparent differential association by tumour grade. Patient summary In this study, we looked at circulating testosterone levels and risk of developing prostate cancer, finding that men with low testosterone had a lower risk of prostate cancer. © 2018 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Published
2018

42. RBM10–TFE3renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break‐apart fluorescencein‐situhybridisation: study of 10 cases and a literature review

Author

Kato, Ikuma, primary, Furuya, Mitsuko, additional, Baba, Masaya, additional, Kameda, Yoichi, additional, Yasuda, Masanori, additional, Nishimoto, Koshiro, additional, Oyama, Masafumi, additional, Yamasaki, Toshinari, additional, Ogawa, Osamu, additional, Niino, Hitoshi, additional, Nakaigawa, Noboru, additional, Yano, Yuta, additional, Sakamoto, Kazumasa, additional, Urata, Yoji, additional, Mikami, Kazuya, additional, Yamasaki, Shigetaka, additional, Tanaka, Reiko, additional, Takagi, Toshio, additional, Kondo, Tsunenori, additional, and Nagashima, Yoji, additional

Published
2019
Full Text
View/download PDF

44. Circulating isoflavone and lignan concentrations and prostate cancer risk : a meta-analysis of individual participant data from seven prospective studies including 2,828 cases and 5,593 controls

Author

Perez-Cornago, Aurora, Appleby, Paul N., Boeing, Heiner, Gil, Leire, Kyro, Cecilie, Ricceri, Fulvio, Murphy, Neil, Trichopoulou, Antonia, Tsilidis, Konstantinos K., Khaw, Kay-Tee, Luben, Robert N., Gislefoss, Randi E., Langseth, Hilde, Drake, Isabel, Sonestedt, Emily, Wallström, Peter, Stattin, Pär, Johansson, Anders, Landberg, Rikard, Nilsson, Lena Maria, Ozasa, Kotaro, Tamakoshi, Akiko, Mikami, Kazuya, Kubo, Tatsuhiko, Sawada, Norie, Tsugane, Shoichiro, Key, Timothy J., Allen, Naomi E., Travis, Ruth C., Perez-Cornago, Aurora, Appleby, Paul N., Boeing, Heiner, Gil, Leire, Kyro, Cecilie, Ricceri, Fulvio, Murphy, Neil, Trichopoulou, Antonia, Tsilidis, Konstantinos K., Khaw, Kay-Tee, Luben, Robert N., Gislefoss, Randi E., Langseth, Hilde, Drake, Isabel, Sonestedt, Emily, Wallström, Peter, Stattin, Pär, Johansson, Anders, Landberg, Rikard, Nilsson, Lena Maria, Ozasa, Kotaro, Tamakoshi, Akiko, Mikami, Kazuya, Kubo, Tatsuhiko, Sawada, Norie, Tsugane, Shoichiro, Key, Timothy J., Allen, Naomi E., and Travis, Ruth C.

Abstract

Phytoestrogens may influence prostate cancer development. This study aimed to examine the association between prediagnostic circulating concentrations of isoflavones (genistein, daidzein, equol) and lignans (enterolactone and enterodiol) and the risk of prostate cancer. Individual participant data were available from seven prospective studies (two studies from Japan with 241 cases and 503 controls and five studies from Europe with 2,828 cases and 5,593 controls). Because of the large difference in circulating isoflavone concentrations between Japan and Europe, analyses of the associations of isoflavone concentrations and prostate cancer risk were evaluated separately. Prostate cancer risk by study-specific fourths of circulating concentrations of each phytoestrogen was estimated using multivariable-adjusted conditional logistic regression. In men from Japan, those with high compared to low circulating equol concentrations had a lower risk of prostate cancer (multivariable-adjusted OR for upper quartile [Q4] vs. Q1 = 0.61, 95% confidence interval [CI] = 0.39-0.97), although there was no significant trend (OR per 75 percentile increase = 0.69, 95 CI = 0.46-1.05, p(trend) = 0.085); Genistein and daidzein concentrations were not significantly associated with risk (ORs for Q4 vs. Q1 = 0.70, 0.45-1.10 and 0.71, 0.45-1.12, respectively). In men from Europe, circulating concentrations of genistein, daidzein and equol were not associated with risk. Circulating lignan concentrations were not associated with the risk of prostate cancer, overall or by disease aggressiveness or time to diagnosis. There was no strong evidence that prediagnostic circulating concentrations of isoflavones or lignans are associated with prostate cancer risk, although further research is warranted in populations where isoflavone intakes are high.

Published
2018
Full Text
View/download PDF

45. Circulating isoflavone and lignan concentrations and prostate cancer risk: a meta-analysis of individual participant data from seven prospective studies including 2,828 cases and 5,593 controls

Author

Perez-Cornago, Aurora, primary, Appleby, Paul N., additional, Boeing, Heiner, additional, Gil, Leire, additional, Kyrø, Cecilie, additional, Ricceri, Fulvio, additional, Murphy, Neil, additional, Trichopoulou, Antonia, additional, Tsilidis, Konstantinos K., additional, Khaw, Kay-Tee, additional, Luben, Robert N., additional, Gislefoss, Randi E, additional, Langseth, Hilde, additional, Drake, Isabel, additional, Sonestedt, Emily, additional, Wallström, Peter, additional, Stattin, Pär, additional, Johansson, Anders, additional, Landberg, Rikard, additional, Nilsson, Lena Maria, additional, Ozasa, Kotaro, additional, Tamakoshi, Akiko, additional, Mikami, Kazuya, additional, Kubo, Tatsuhiko, additional, Sawada, Norie, additional, Tsugane, Shoichiro, additional, Key, Timothy J., additional, Allen, Naomi E., additional, and Travis, Ruth C., additional

Published
2018
Full Text
View/download PDF

46. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma

Author

Hagiwara, Nobuhisa, primary, Watanabe, Motoki, additional, Iizuka-Ohashi, Mahiro, additional, Yokota, Isao, additional, Toriyama, Seijiro, additional, Sukeno, Mamiko, additional, Tomosugi, Mitsuhiro, additional, Sowa, Yoshihiro, additional, Hongo, Fumiya, additional, Mikami, Kazuya, additional, Soh, Jintetsu, additional, Fujito, Akira, additional, Miyashita, Hiroaki, additional, Morioka, Yukako, additional, Miki, Tsuneharu, additional, Ukimura, Osamu, additional, and Sakai, Toshiyuki, additional

Published
2018
Full Text
View/download PDF

47. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk

Author

Travis, Ruth, Appleby, Paul, Martin, Richard, Holly, Jeff M.P., Albanes, Demetrius, Black, Amanda, Bueno-De-Mesquita, H. Bas, Chan, June, Chen, Chu, Chirlaque, María-Dolores, Cook, Michael, Deschasaux, Mélanie, Donovan, Jenny, Ferrucci, Luigi, Galan, Pilar, Giles, Graham, Giovannucci, Edward, Gunter, Marc, Habel, Laurel, Hamdy, Freddie, Helzlsouer, Kathy, Hercberg, Serge, Hoover, Robert, Janssen, Joseph A.M.J.L., Kaaks, Rudolf, Kubo, Tatsuhiko, Le Marchand, Loïc, Metter, E. Jeffrey, Mikami, Kazuya, Morris, Joan, Neal, David, Neuhouser, Marian, Ozasa, Kotaro, Palli, Domenico, Platz, Elizabeth, Pollak, Michael, Price, Alison, Roobol, Monique, Schaefer, Catherine, Schenk, Jeannette, Severi, Gianluca, Stampfer, Meir, Stattin, Pär, Tamakoshi, Akiko, Tangen, Catherine, Touvier, Mathilde, Wald, Nicholas, Weiss, Noel, Ziegler, Regina, Key, Timothy, Allen, Naomi, Nuffield Department of Population Health [Oxford], University of Oxford [Oxford], School of Social and Community Medicine [Bristol], University of Bristol [Bristol], National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), National Institute for Public Health and the Environment [Bilthoven] (RIVM), University of California [San Francisco] (UCSF), University of California, Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública (CIBERESP), Los Centros de Investigación Biomédica en Red (CIBER), Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute on Aging [Bethesda, USA] (NIA), University of Melbourne, Harvard School of Public Health, School of Public Health - Department of Epidemiology and Biostatistics, Imperial College London, Kaiser Permanente, Nuffield (Nuffield), Mercy Medical Center, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), University of Occupational and Environmental Health [Kitakyushu] (UEOH), University of Hawai‘i [Mānoa] (UHM), Kyoto Prefectural University of Medicine [Kyoto, Japon], Queen Mary University of London (QMUL), University of Cambridge [UK] (CAM), Radiation Effects Research Foundation, Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU), Cancer Prevention Research Unit, Department of Oncology, McGill University = Université McGill [Montréal, Canada]-Jewish General Hospital, University of Washington [Seattle], Cancer Epidemiology Centre, Cancer Council Victoria, Human Genetics Foundation (HuGeF), Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Hokkaido University Hospital [Sapporo], University of Oxford, University of California [San Francisco] (UC San Francisco), University of California (UC), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), and Deschasaux-Tanguy, Mélanie

Subjects
Urologic Diseases, Male, Aging, Oncology and Carcinogenesis, Article, growth-factor-i, serum-insulin, Risk Factors, prevention trial, Humans, Oncology & Carcinogenesis, Insulin-Like Growth Factor I, factor axis, igfbp-3, Cancer, Aged, Prostate Cancer, hyperplasia, Prostatic Neoplasms, Middle Aged, susceptibility loci, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, factor-binding protein-2, Centre for Surgical Research, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, factor (igf)-i, diet, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Abstract

The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from 17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. Aftermutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development.

Published
2016

48. Management of Side Effects of Everolimus Treatment for Metastatic Renal Cell Carcinoma

Author

Mikami, Kazuya, Hongo, Fumiya, and Miki, Tsuneharu

Subjects
Metastatic RCC, Everolimus, 494.9, Side effects, ILD
Abstract

Treatment with everolimus is known to prolong progression-free survival in patients with renal cell carcinoma resistant against tyrosine-kinase inhibitor therapy. The side effects must be known for more effective use of this drug. Information of side effects was collected from a randomized controlled study, the early post-marketing phase vigilance and from our own experience. Interstitial lung disease (ILD) was a potentially severe side effect. Incidence of ILD was relatively large compared with that of other target therapy agents. Infections, thrombocytopenia, stomatitis and others were experienced as other side effects. However, there were few uncontrollable side effects. Management of side effects of everolimus can be improved by obtaining sufficient knowledge.

Published
2012

49. Squamous cell carcinoma of the renal pelvis with elevation of G-CSF in the serum: a case report

Author

Fujii, Hidetaka, Nakamura, Terukazu, Mikami, Kazuya, Okihara, Koji, Mizutani, Yoichi, Kawauchi, Akihiro, and Miki, Tsuneharu

Subjects
SCC antigen, Renal pelvis cancer, 494.9, G-CSF, Granulocyte-colony stimulating factor
Abstract

67歳男。患者は左腰背部痛と尿混濁を主訴に近医を受診, 腎超音波検査ならびに腹部CTにて左腎盂腫瘍が疑われ, 著者らの施設へ紹介受診となった。所見ではWBC, SCC抗原, G-CSF高値が認められ, 尿細胞診はclass IIであった。腹部CTでは左腎盂内から腎実質へ浸潤する充実性腫瘍がみられ, 周囲脂肪織, 腸腰筋浸潤も疑われた。WBCは異常高値であったが血液疾患は否定的で, 感染兆候もなかった。以上より, 本症例は血清G-CSF高値を伴う左腎盂扁平上皮癌と診断され, 術前化学療法としてM-VAC療法が2コース施行されたが, 全身倦怠感, 食欲不振が続き, パクリタキセル+ネダプラチンが2クール追加施行された。その結果, SCC抗原とG-CSFはともに低下し, 術前までに腫瘍は著明に縮小した。以後, 左腎尿管全摘除術を施行したところ, 腫瘍の大部分は壊死に陥っていた。術後は血清SCC, G-CSF値は正常化し, 希望により後療法は行なわれなかったが, 初診から4年以上が経過する現在, 再発の兆候は認められていない。, A 67-year-old man was admitted with left renal pelvic tumor. He had a leukocytosis of 26, 500/mm3 (neutrophils: 81.7%) in the peripheral blood, but with no obvious focus of infection. Moreover, the serum granulocyte-colony stimulating factor (G-CSF) and squamous cell carcinoma antigen (SCC) were elevated. Abdominal enhanced computed tomography (CT) and left retrograde pyelography showed left renal pelvic cancer T4N0M0. He received neoadjuvant chemotherapy (M-VAC: cisplatin + methotrexate + vinblastin + doxorubicin, TN: paclitaxel + nedaplatin). After neoadjuvant chemotherapy, left nephroureterectomy was performed because of normalization of the serum SCC and G-CSF. Histological examination revealed squamous cell carcinoma of the renal pelvis. He is alive with no evidence of disease for 4 years.

Published
2008

50. Randomized study of intravesical chemotherapy using pirarubicin in patients with non-muscle-invasive bladder cancer in Japan: Comparing one immediate postoperative intravesical chemotherapy with short-term adjuvant intravesical chemotherapy after TURBT: Subanalysis in patients with intermediate risk.

Author

Naya, Yoshio, primary, Mikami, Kazuya, additional, Takaha, Natsuki, additional, Okihara, Koji, additional, Miki, Tsuneharu, additional, and Ukimura, Osamu, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results